A Phase I study of ISIS-PKKRx for the treatment of hereditary angioedema (HAE)

Trial Profile

A Phase I study of ISIS-PKKRx for the treatment of hereditary angioedema (HAE)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2015

At a glance

  • Drugs IONIS PKKRx (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man
  • Sponsors Isis Pharmaceuticals
  • Most Recent Events

    • 24 Feb 2015 Results published in an Isis Pharmaceuticals media release.
    • 24 Feb 2015 Status changed from recruiting to completed, as reported in an Isis Pharmaceuticals media release.
    • 16 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top